Review




Structured Review

Medeor Therapeutics cellular immunotherapy
Cellular Immunotherapy, supplied by Medeor Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/cellular+immunotherapy/nct05010174-3-6-6
Average 90 stars, based on 1 article reviews
cellular immunotherapy - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

CRISPR:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Transplantation Assay:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

In Utero:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Plasmid Preparation:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Virus:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Variant Assay:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Transduction:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.

Genetically Modified:

Article Title: Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Article Snippet: Daniel Brennan (Medeor) reported on a similar TLI/ATG/CD34 cell infusion trial in HLA-identical KTx recipients.

Article Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Article Snippet: Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: At the completion of primary follow-up of various Medeor kidney transplant studies (called parent studies), subjects receiving Medeor’s cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years) for long-term safety evaluation.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: Within 3 months of completion of a Medeor clinical trial, the kidney transplant recipients who received a Medeor cellular immunotherapy product will begin annual study MDR-105-SAE visits at 12 months (with an allowed deviation of ± 1 month for scheduled annual visits).

Article Title: The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects
Article Snippet: MDR-101 (cellular therapy comprising kidney donor-derived CD34 + HSCs and CD3 + T cells) , Medeor Therapeutics , Prevent kidney transplant rejection without chronic use of immunosuppressive drugs , 22/09/2020.

Article Title: Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeor’s cellular immunotherapy products: the MDR-105-SAE
Article Snippet: The study population will consist of kidney transplant recipients who received Medeor’s cellular immunotherapy in its previous and future kidney transplant studies.



Similar Products

95
Dojindo Labs cellular senescence detection kit spider β gal
a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent <t>(SPiDER-β-Gal</t> + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).
Cellular Senescence Detection Kit Spider β Gal, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Cellular+Senescence+Detection+Kit+-+SPiDER+Blue/pmc13754587-391-8-13
Average 95 stars, based on 1 article reviews
cellular senescence detection kit spider β gal - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
Medeor Therapeutics medeor's cellular products
a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent <t>(SPiDER-β-Gal</t> + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).
Medeor's Cellular Products, supplied by Medeor Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/medeor+matrix/nct05010174-1-24-24
Average 90 stars, based on 1 article reviews
medeor's cellular products - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Medeor Therapeutics cellular immunotherapy
a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent <t>(SPiDER-β-Gal</t> + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).
Cellular Immunotherapy, supplied by Medeor Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/cellular+immunotherapy/nct05010174-3-6-6
Average 90 stars, based on 1 article reviews
cellular immunotherapy - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Elabscience Biotechnology cellular oxygen consumption
a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent <t>(SPiDER-β-Gal</t> + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).
Cellular Oxygen Consumption, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Oxygen+Consumption+Rate+(OCR)+Fluorometric+Assay+Kit/pmc13771983-304-0-13
Average 95 stars, based on 1 article reviews
cellular oxygen consumption - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Beyotime cellular senescence assay kit
scRNA-seq analysis results A) Uniform Manifold Approximation and Projection (UMAP) plot showing the major cell types in prostate cancer samples, with individual cells represented as dots and different cell populations distinguished by colors. B) UMAP plot showing the distribution of cells treated with endocrine therapy and those not treated with endocrine therapy. Individual cells are represented as dots, with different colors distinguishing the two treatment groups. C) Box plot showing the distribution of SASP scores in all cells with and without endocrine therapy. D) Box plot showing the distribution of SASP scores in all epithelial cells with and without endocrine therapy. E) Box plot showing the distribution of the mean SASP scores of epithelial cells per sample with and without endocrine therapy. F) Violin plot showing the expression distribution of the key <t>senescence</t> gene CDKN2B with and without endocrine therapy. G) Box plot showing the distribution of senescence scores in prostate cancer samples from the GSE150368 dataset with and without therapy. H) Box plot showing the difference in MDSCs scores in prostate cancer samples with and without endocrine therapy from the GSE150368 dataset. I) Scatter plot showing the correlation between senescence scores and MDSCs scores in individual prostate cancer samples from the GSE150368 dataset. J) Representative immunofluorescence images of prostate cancer tissue sections from patients without or with prior endocrine therapy. Three specimens are shown for each group. Sections were stained for the senescence-associated proteins p16 (red) and p21 (green), with nuclei counterstained with DAPI (blue). Upper row, untreated specimens; lower row, endocrine therapy-treated specimens. Scale bar, 250 μm.
Cellular Senescence Assay Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Senescence+%CE%B2-Galactosidase+Staining+Kit/pmc13771463-395-33-37
Average 99 stars, based on 1 article reviews
cellular senescence assay kit - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC vitro cellular test l929 mouse fibroblast cells
scRNA-seq analysis results A) Uniform Manifold Approximation and Projection (UMAP) plot showing the major cell types in prostate cancer samples, with individual cells represented as dots and different cell populations distinguished by colors. B) UMAP plot showing the distribution of cells treated with endocrine therapy and those not treated with endocrine therapy. Individual cells are represented as dots, with different colors distinguishing the two treatment groups. C) Box plot showing the distribution of SASP scores in all cells with and without endocrine therapy. D) Box plot showing the distribution of SASP scores in all epithelial cells with and without endocrine therapy. E) Box plot showing the distribution of the mean SASP scores of epithelial cells per sample with and without endocrine therapy. F) Violin plot showing the expression distribution of the key <t>senescence</t> gene CDKN2B with and without endocrine therapy. G) Box plot showing the distribution of senescence scores in prostate cancer samples from the GSE150368 dataset with and without therapy. H) Box plot showing the difference in MDSCs scores in prostate cancer samples with and without endocrine therapy from the GSE150368 dataset. I) Scatter plot showing the correlation between senescence scores and MDSCs scores in individual prostate cancer samples from the GSE150368 dataset. J) Representative immunofluorescence images of prostate cancer tissue sections from patients without or with prior endocrine therapy. Three specimens are shown for each group. Sections were stained for the senescence-associated proteins p16 (red) and p21 (green), with nuclei counterstained with DAPI (blue). Upper row, untreated specimens; lower row, endocrine therapy-treated specimens. Scale bar, 250 μm.
Vitro Cellular Test L929 Mouse Fibroblast Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/NCTC+clone+929/10__3390_slash_gels12111013-249-1-8
Average 99 stars, based on 1 article reviews
vitro cellular test l929 mouse fibroblast cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
Dojindo Labs cellular senescence detection kit spider βgal

Cellular Senescence Detection Kit Spider βgal, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Cellular+Senescence+Detection+Kit+-+SPiDER-BGal/pmc13755965-60-0-7
Average 95 stars, based on 1 article reviews
cellular senescence detection kit spider βgal - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Beyotime cellular senescence βalactosidase staining kit

Cellular Senescence βalactosidase Staining Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Senescence+%CE%B2-Galactosidase+Staining+Kit/pm42977866-406-26-25
Average 99 stars, based on 1 article reviews
cellular senescence βalactosidase staining kit - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
Elabscience Biotechnology cellular ferrous iron

Cellular Ferrous Iron, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular/Cell+Ferrous+Iron+Colorimetric+Assay+Kit/pmc13773898-179-5-19
Average 97 stars, based on 1 article reviews
cellular ferrous iron - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

Image Search Results


a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent (SPiDER-β-Gal + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).

Journal: Nature Aging

Article Title: Altered protein cysteine reactivity in senescent cells is a vulnerability for senolysis to ameliorate aging

doi: 10.1038/s43587-026-01253-5

Figure Lengend Snippet: a , Schematic of the GSSG–GSH interconversion pathway. b , Changes in GSR and GPx gene expression in senescent cells, quantified by RT–quantitative PCR. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells for BJ and HCA2 cells; n = 3 wells for A549 cells). c , Changes in GSR and GPx enzymatic activity in senescent cells. Fold change was normalized to the corresponding nonsenescent cells in each model ( n = 4 wells). d , Changes in Gsr and GPx gene expression in senescent cells isolated from mouse liver and kidney. Senescent (SPiDER-β-Gal + ) and nonsenescent (SPiDER-β-Gal − ) cells were sorted from 76-week-old mice and analyzed by RT–quantitative PCR (kidney, n = 4 independent experiments; liver, n = 3 independent experiments). e , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells treated with the GSR inhibitor 2-AAPA (6 h), sodium selenite (48 h, to enhance GPx activity) or sodium selenite for 48 h followed by 2-AAPA for 6 h ( n = 3 triplicate wells). f , Cell viability of nonsenescent BJ cells following treatment with 2-AAPA, sodium selenite or their combination, in response to VS ( n = 3 triplicate wells). g , Relative GSSG levels, GSH levels and GSH/GSSG ratios in nonsenescent BJ cells following GSR knockdown by siRNA (36 h) ( n = 3 triplicate wells). h , Cell viability of nonsenescent BJ cells after GSR knockdown in response to VS ( n = 3 triplicate wells). Data in b – d are presented as bubble plots showing fold change and P values. Data are presented as mean ± s.d. ( e – h ). Statistical analysis was performed using two-sided unpaired Student’s t -test ( b – d ) or two-way ANOVA ( e – h ).

Article Snippet: After centrifugation, SA-β-Gal staining was performed using the cellular senescence detection kit SPiDER-β-Gal (Dojindo Molecular Technologies, SG0403) according to the manufacturer’s instructions.

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Activity Assay, Isolation, Knockdown, Analysis

scRNA-seq analysis results A) Uniform Manifold Approximation and Projection (UMAP) plot showing the major cell types in prostate cancer samples, with individual cells represented as dots and different cell populations distinguished by colors. B) UMAP plot showing the distribution of cells treated with endocrine therapy and those not treated with endocrine therapy. Individual cells are represented as dots, with different colors distinguishing the two treatment groups. C) Box plot showing the distribution of SASP scores in all cells with and without endocrine therapy. D) Box plot showing the distribution of SASP scores in all epithelial cells with and without endocrine therapy. E) Box plot showing the distribution of the mean SASP scores of epithelial cells per sample with and without endocrine therapy. F) Violin plot showing the expression distribution of the key senescence gene CDKN2B with and without endocrine therapy. G) Box plot showing the distribution of senescence scores in prostate cancer samples from the GSE150368 dataset with and without therapy. H) Box plot showing the difference in MDSCs scores in prostate cancer samples with and without endocrine therapy from the GSE150368 dataset. I) Scatter plot showing the correlation between senescence scores and MDSCs scores in individual prostate cancer samples from the GSE150368 dataset. J) Representative immunofluorescence images of prostate cancer tissue sections from patients without or with prior endocrine therapy. Three specimens are shown for each group. Sections were stained for the senescence-associated proteins p16 (red) and p21 (green), with nuclei counterstained with DAPI (blue). Upper row, untreated specimens; lower row, endocrine therapy-treated specimens. Scale bar, 250 μm.

Journal: Bioactive Materials

Article Title: PSMA-targeted nanoparticles delivering ATR and Src/Bcr-Abl inhibitors to stimulate STING and reprogram senescence-associated secretory phenotype for enhancing immunotherapy in prostate cancer

doi: 10.1016/j.bioactmat.2026.10.033

Figure Lengend Snippet: scRNA-seq analysis results A) Uniform Manifold Approximation and Projection (UMAP) plot showing the major cell types in prostate cancer samples, with individual cells represented as dots and different cell populations distinguished by colors. B) UMAP plot showing the distribution of cells treated with endocrine therapy and those not treated with endocrine therapy. Individual cells are represented as dots, with different colors distinguishing the two treatment groups. C) Box plot showing the distribution of SASP scores in all cells with and without endocrine therapy. D) Box plot showing the distribution of SASP scores in all epithelial cells with and without endocrine therapy. E) Box plot showing the distribution of the mean SASP scores of epithelial cells per sample with and without endocrine therapy. F) Violin plot showing the expression distribution of the key senescence gene CDKN2B with and without endocrine therapy. G) Box plot showing the distribution of senescence scores in prostate cancer samples from the GSE150368 dataset with and without therapy. H) Box plot showing the difference in MDSCs scores in prostate cancer samples with and without endocrine therapy from the GSE150368 dataset. I) Scatter plot showing the correlation between senescence scores and MDSCs scores in individual prostate cancer samples from the GSE150368 dataset. J) Representative immunofluorescence images of prostate cancer tissue sections from patients without or with prior endocrine therapy. Three specimens are shown for each group. Sections were stained for the senescence-associated proteins p16 (red) and p21 (green), with nuclei counterstained with DAPI (blue). Upper row, untreated specimens; lower row, endocrine therapy-treated specimens. Scale bar, 250 μm.

Article Snippet: After 12 h of incubation, cells were treated with Ber, Ber + Das and T-Lipo@Das/Ber with final concentrations of 20 μM for 48 h. Then, the SAβG activity was analyzed by using the Cellular Senescence Assay Kit (Beyotime) according to the manufacturer's instructions.

Techniques: Analysis, Expressing, Immunofluorescence, Tissue, Staining

In vitro T-Lipo@Das/Ber activates the cGAS-STING pathway via DNA damage and induces cellular senescence through mitochondrial dysfunction. A, B) Representative CLSM images and semi-quantification of the expression of γ-H2AX in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The γ-H2AX was stained with green. C, D) Representative CLSM images and semi-quantification of the dsDNA in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The dsDNA was stained with green. E, F) Representative CLSM images and semi-quantification of the expression of P-STING in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The P-STING was stained with red. G, H) Representative flow cytometric profiles and semi-quantification of the expression of P-STING in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The P-STING was stained with FITC. I) Representative images of SA-β-gal-stained PC-3 cells following the indicated treatments. J, K) Representative CLSM images and quantification of mitochondrial membrane potential in PC-3 cells following the indicated treatments. Data are represented as mean ± SD. Statistical significances between every two groups were calculated via one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Bioactive Materials

Article Title: PSMA-targeted nanoparticles delivering ATR and Src/Bcr-Abl inhibitors to stimulate STING and reprogram senescence-associated secretory phenotype for enhancing immunotherapy in prostate cancer

doi: 10.1016/j.bioactmat.2026.10.033

Figure Lengend Snippet: In vitro T-Lipo@Das/Ber activates the cGAS-STING pathway via DNA damage and induces cellular senescence through mitochondrial dysfunction. A, B) Representative CLSM images and semi-quantification of the expression of γ-H2AX in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The γ-H2AX was stained with green. C, D) Representative CLSM images and semi-quantification of the dsDNA in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The dsDNA was stained with green. E, F) Representative CLSM images and semi-quantification of the expression of P-STING in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The P-STING was stained with red. G, H) Representative flow cytometric profiles and semi-quantification of the expression of P-STING in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The P-STING was stained with FITC. I) Representative images of SA-β-gal-stained PC-3 cells following the indicated treatments. J, K) Representative CLSM images and quantification of mitochondrial membrane potential in PC-3 cells following the indicated treatments. Data are represented as mean ± SD. Statistical significances between every two groups were calculated via one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: After 12 h of incubation, cells were treated with Ber, Ber + Das and T-Lipo@Das/Ber with final concentrations of 20 μM for 48 h. Then, the SAβG activity was analyzed by using the Cellular Senescence Assay Kit (Beyotime) according to the manufacturer's instructions.

Techniques: In Vitro, Expressing, Staining, Membrane

T-Lipo@Das/Ber induces senescence and reprograms the SASP to trigger immunogenic cell death in vitro . A, B) Representative CLSM images and semi-quantification of the expression of HMGB1 in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The HMGB1 was stained with green. C, D) Representative CLSM images and semi-quantification of the exposure of CRT in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The CRT was stained with green. E, F) Flow cytometry scatter plot for DC activation cocultured with PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber, and quantification of matured BMDCs rate. G) T-Lipo@Das/Ber delivers Ber to activate the cGAS-STING pathway and Das to reprogram SASP, synergistically enhancing immunogenicity and immune cell activation. Data are represented as mean ± SD. Statistical significances between every two groups were calculated via one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Journal: Bioactive Materials

Article Title: PSMA-targeted nanoparticles delivering ATR and Src/Bcr-Abl inhibitors to stimulate STING and reprogram senescence-associated secretory phenotype for enhancing immunotherapy in prostate cancer

doi: 10.1016/j.bioactmat.2026.10.033

Figure Lengend Snippet: T-Lipo@Das/Ber induces senescence and reprograms the SASP to trigger immunogenic cell death in vitro . A, B) Representative CLSM images and semi-quantification of the expression of HMGB1 in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The HMGB1 was stained with green. C, D) Representative CLSM images and semi-quantification of the exposure of CRT in PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber. The CRT was stained with green. E, F) Flow cytometry scatter plot for DC activation cocultured with PC-3 cells treated with Ber, Ber + Das and T-Lipo@Das/Ber, and quantification of matured BMDCs rate. G) T-Lipo@Das/Ber delivers Ber to activate the cGAS-STING pathway and Das to reprogram SASP, synergistically enhancing immunogenicity and immune cell activation. Data are represented as mean ± SD. Statistical significances between every two groups were calculated via one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: After 12 h of incubation, cells were treated with Ber, Ber + Das and T-Lipo@Das/Ber with final concentrations of 20 μM for 48 h. Then, the SAβG activity was analyzed by using the Cellular Senescence Assay Kit (Beyotime) according to the manufacturer's instructions.

Techniques: In Vitro, Expressing, Staining, Flow Cytometry, Activation Assay, Immunopeptidomics, Immune Cell

Journal: iScience

Article Title: TRPM2-mediated Ca 2+ entry drives cellular senescence to irradiation-induced salivary gland dysfunction

doi: 10.1016/j.isci.2026.118109

Figure Lengend Snippet:

Article Snippet: Cellular Senescence Detection Kit - SPiDER-βGal , Dojindo Molecular Technologies , Cat# SG04-01.

Techniques: